183 related articles for article (PubMed ID: 29648903)
1. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors.
Hu H; Zhang W; Huang D; Yang Q; Li J; Gao Y
Pediatr Hematol Oncol; 2018 Mar; 35(2):111-120. PubMed ID: 29648903
[TBL] [Abstract][Full Text] [Related]
2. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
3. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
[TBL] [Abstract][Full Text] [Related]
4. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
[TBL] [Abstract][Full Text] [Related]
6. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.
Pongprot Y; Sittiwangkul R; Charoenkwan P; Silvilairat S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):589-95. PubMed ID: 23018571
[TBL] [Abstract][Full Text] [Related]
7. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
8. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
[TBL] [Abstract][Full Text] [Related]
10. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
[TBL] [Abstract][Full Text] [Related]
11. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
[TBL] [Abstract][Full Text] [Related]
12. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
[TBL] [Abstract][Full Text] [Related]
14. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
15. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
17. Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.
Jacobse JN; Steggink LC; Sonke GS; Schaapveld M; Hummel YM; Steenbruggen TG; Lefrandt JD; Nuver J; Crijns APG; Aleman BMP; van der Meer P; Gietema JA; van Leeuwen FE
Eur J Heart Fail; 2020 Feb; 22(2):338-346. PubMed ID: 31696625
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of NT-ProBNP as an early cardiac marker of carbon monoxide poisoning.
Davutoglu V; Gunay N; Kocoglu H; Gunay NE; Yildirim C; Cavdar M; Tarakcioglu M
Inhal Toxicol; 2006 Feb; 18(2):155-8. PubMed ID: 16393930
[TBL] [Abstract][Full Text] [Related]
19. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
[TBL] [Abstract][Full Text] [Related]
20. Long-term cardiac effects of treatment for childhood leukemia.
Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
